Johnson & Johnson logo

Johnson & Johnson (JNJCL)

Market Open
22 Jul, 19:00
XSGO XSGO
157,050. 00
CLP
0
0%
CLP
- Market Cap
29.06 P/E Ratio
4.96% Div Yield
14 Volume
9.91 Eps
157,050 CLP
Previous Close
Day Range
157,050 159,600
Year Range
138,900 159,600
Want to track JNJCL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 83 days

Summary

JNJCL trading today higher at 157,050 CLP, an increase of 0% from yesterday's close, completing a monthly increase of 1.98% or 3,050 CLP. Over the past 12 months, JNJCL stock gained 8.33%.
JNJCL pays dividends to its shareholders, with the most recent payment made on Jun 10, 2025. The next estimated payment will be in In 1 month on Sep 10, 2025 for a total of 1.3 CLP.
The last earnings report, released on Jul 16, 2025, exceeded the consensus estimates by 0.09%. On average, the company has surpassed earnings expectations by 0.04%, based on the last three reports. The next scheduled earnings report is due on Oct 14, 2025.
Johnson & Johnson has completed 6 stock splits, with the recent split occurring on Jun 13, 2001.
The company's stock is traded on 19 different exchanges and in various currencies, with the primary listing on NYSE (USD).

JNJCL Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
4 Major Stocks Raise 2025 Guidance, Analyst Targets Rise

4 Major Stocks Raise 2025 Guidance, Analyst Targets Rise

A wave of upgraded guidance from major U.S. companies is reshaping the outlook for the rest of 2025, and analysts are responding in kind. Strong Q2 earnings results have prompted several high-profile firms to lift their full-year forecasts, triggering a flurry of price target hikes across Wall Street.

Marketbeat | 2 hours ago
Johnson & Johnson Stock Could Be Waking Up

Johnson & Johnson Stock Could Be Waking Up

Johnson & Johnson's stock appears undervalued, as sluggish revenue growth and margin contraction are offset by raised full-year guidance and a rebounding outlook. Both Innovative Medicine and MedTech segments show promising pipeline developments, with MedTech's growth and robotics ambitions offering future upside. Despite a dip in free cash flow, J&J's dividend remains attractive, with a solid 3.18% yield and a 62-year growth streak, supporting shareholder returns.

Seekingalpha | 18 hours ago
JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra

JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra

Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque psoriasis.

Zacks | 21 hours ago

Johnson & Johnson Dividends

Johnson & Johnson logo
JNJ In 1 month
Estimated
Quarterly
$1.3 Per Share
Johnson & Johnson logo
JNJ 1 month ago
Paid
Quarterly
$1.3 Per Share
Johnson & Johnson logo
JNJ 5 months ago
Paid
Quarterly
$1.24 Per Share
Johnson & Johnson logo
JNJ 7 months ago
Paid
Quarterly
$1.24 Per Share
Johnson & Johnson logo
JNJ 10 months ago
Paid
Quarterly
$1.24 Per Share
Johnson & Johnson logo
JNJ 20 May 2024
Paid
Quarterly
$1.24 Per Share

Johnson & Johnson Earnings

14 Oct 2025 (In 2 months) Date
2.75
Cons. EPS
-
EPS
16 Jul 2025 Date
2.68
Cons. EPS
2.77
EPS
14 Apr 2025 Date
-
Cons. EPS
-
EPS
22 Jan 2025 Date
2.01
Cons. EPS
2.04
EPS
21 Jan 2025 Date
-
Cons. EPS
-
EPS
Johnson & Johnson logo
JNJ In 1 month
Estimated
Quarterly
$1.3 Per Share
Johnson & Johnson logo
JNJ 1 month ago
Paid
Quarterly
$1.3 Per Share
Johnson & Johnson logo
JNJ 5 months ago
Paid
Quarterly
$1.24 Per Share
Johnson & Johnson logo
JNJ 7 months ago
Paid
Quarterly
$1.24 Per Share
Johnson & Johnson logo
JNJ 10 months ago
Paid
Quarterly
$1.24 Per Share
Johnson & Johnson logo
JNJ 20 May 2024
Paid
Quarterly
$1.24 Per Share
14 Oct 2025 (In 2 months) Date
2.75
Cons. EPS
-
EPS
16 Jul 2025 Date
2.68
Cons. EPS
2.77
EPS
14 Apr 2025 Date
-
Cons. EPS
-
EPS
22 Jan 2025 Date
2.01
Cons. EPS
2.04
EPS
21 Jan 2025 Date
-
Cons. EPS
-
EPS

Johnson & Johnson (JNJCL) FAQ

What is the stock price today?

The current price is 157,050.00 CLP.

On which exchange is it traded?

Johnson & Johnson is listed on NYSE.

What is its stock symbol?

The ticker symbol is JNJCL.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 4.96%.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 2.75.

When is the next earnings date?

The next earnings report will release on Oct 14, 2025.

Has Johnson & Johnson ever had a stock split?

Johnson & Johnson had 6 splits and the recent split was on Jun 13, 2001.

Johnson & Johnson Profile

Drug Manufacturers - General Industry
Healthcare Sector
Joaquin Duato CEO
XSGO Exchange
US4781601046 ISIN
US Country
138,100 Employees
18 Feb 2025 Last Dividend
13 Jun 2001 Last Split
- IPO Date

Overview

Johnson & Johnson, a renowned entity in the healthcare sector, operates globally with a broad focus on research, development, manufacturing, and sales of healthcare products. The company is structured in multiple segments, primarily Innovative Medicine and MedTech, catering to a vast array of therapeutic areas and medical needs. Founded in 1886, the company is headquartered in New Brunswick, New Jersey, illustrating a longstanding presence and commitment to healthcare innovation and advancement. Through its extensive product line and diversified service offerings, Johnson & Johnson reaches a wide audience, including retailers, wholesalers, distributors, hospitals, and healthcare professionals, providing prescription and non-prescription products alike.

Products and Services

The company's portfolio is divided into two main segments, each encompassing a variety of products and services designed to meet the complex demands of modern healthcare:

  • Innovative Medicine:

    This segment includes a range of products for different therapeutic areas. These encompass immunology (covering diseases like rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis), infectious diseases (including HIV/AIDS treatment), neuroscience (targeting mood disorders, neurodegenerative disorders, schizophrenia), oncology (focused on cancers such as prostate, lung, bladder, and hematologic malignancies), cardiovascular and metabolism (addressing conditions like thrombosis, diabetes, and macular degeneration), and pulmonary hypertension, specifically pulmonary arterial hypertension.

  • MedTech:

    This segment offers products and technologies across a range of medical fields. Interventional Solutions include electrophysiology products for heart rhythm disorders and technologies for severe coronary artery disease treatment. The neurovascular care line focuses on treating hemorrhagic and ischemic strokes. Orthopaedics products support treatments for hips, knees, trauma, spine, and sports injuries. The surgery portfolio covers advanced and general surgery technologies and solutions for breast aesthetics and ear, nose, and throat procedures. Additionally, MedTech offers visual health products like ACUVUE Brand contact lenses and TECNIS intraocular lenses for cataract surgery.

Contact Information

Address: One Johnson & Johnson Plaza
Phone: 732 524 0400